Gilead prices Covid-19 drug candidate remdesivir at $2,340 per patient
Published Jun 29, 2020 09:00pm Gilead prices Covid-19 drug candidate remdesivir at $2,340 per patient REUTERS Gilead Sciences Inc has priced its Covid-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from a cheap steroid. The price tag is below the $5,080 per course recommendation by a US drug pricing research group, the Institute for Clinical and Economic Review (ICER), last week. But it is more in line with a lower range suggested by ICER of around $2,520 to $2,800, if cheap steroid dexamethasone, which is not patent-protected, is cleared for use in Covid-19. Remdesivir is at the forefront of the fight against Covid-19 after the anti-viral treatment helped shorten hospital recovery times in a clinical trial. It has been approved for emergency use in some patients in the US. Related: Five firms in Pakistan, India allowed to make and sell re...